Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer
cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways
to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. An autologous stem cell transplant may be able to replace blood-forming cells that
were destroyed by lenalidomide and azacitidine. Giving autologous lymphocytes after the
transplant may help destroy any remaining cancer cells.
PURPOSE: This pilot trial is studying how well giving lenalidomide together with azacitidine
works when followed by autologous stem cell transplant and autologous lymphocyte infusion in
treating patients with multiple myeloma.
Phase:
N/A
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborators:
Celgene Corporation National Cancer Institute (NCI)